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Abstract	The increasing prevalence of stroke, with an estimated annual cost of $71.5 billion, has made it a
major health problem that increases disability and death, particularly in patients with atrial fibrillation.
Although advanced age and atrial fibrillation are recognized as strong risk factors for stroke, the
basis for this susceptibility are not well defined. Aging or associated diseases are accompanied by
changes in rheostatic, humoral, metabolic and hemodynamic factors that may contribute more to
stroke predisposition than rhythm abnormality alone. Several thromboembolism-predisposing clinical
characteristics and serum biomarkers with prognostic significance have been identified in patients
with atrial fibrillation. Although anticoagulation decreases the risk of thromboembolism, management
in the elderly remains complex due to major concerns about bleeding. New anticoagulants and
nonpharmacologic strategies are helpful to reduce the risk of bleeding, particularly in older-elderly
patients. Herein, we review the pathogenesis and management of select issues of thromboembolism
in the elderly with atrial fibrillation. (J Patient Cent Res Rev. 2016;3:217-229.)
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Atrial fibrillation (AF) is the most common cardiac
arrhythmia, primarily affecting the senescent heart. Its
increase with age is apparent in the greater prevalence
of AF in octogenarians than in patients younger than
55 years old (9%–10% vs 0.1%, respectively, a 100fold increase).1-3 Thromboembolic stroke is one of
the most feared complications of atrial fibrillation. In
2013, there were 6.5 million stroke deaths worldwide,
making stroke the second-leading global cause of
death behind ischemic heart disease.4 Each year, about
795,000 people in the United States experience a new
or recurrent stroke. Approximately 610,000 of these are
first episodes; 185,000 are recurrent ones. On average,
every 40 seconds, someone in the United States has a
stroke.2 Projections show that by 2030 an additional 3.4
million adults will have had a stroke, a 20.5% increase
in prevalence from 2012.2

AF is a powerful risk factor for stroke, independently
increasing risk about fivefold in those with nonvalvular AF
and more than 20-fold in those with mitral stenosis, with a
very high risk of recurrent stroke, disability and mortality.5
The percentage of strokes attributable to AF increases
steeply from 1.5% at 50–59 years of age to 23.5% at 80–
89 years. The average stroke rate was reported at 4.1%
per year among the primary prevention studies for AF and
13% per year among those with prior stroke or transient
ischemic attack (TIA).1 Important risk factors for stroke
in the setting of AF include advancing age, hypertension,
heart failure, diabetes mellitus, previous stroke or TIA,
vascular disease and female sex. Additional circulating
biomarkers of fibrosis or cardiac stress, including high
levels of troponin and brain natriuretic peptide, increase
the risk of stroke in the setting of AF independent of those
well-established clinical characteristics.6,7
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Women accounted for 58% of U.S. stroke deaths in
2013.2 More women than men die of stroke each year
because of the larger number of elderly women. In the
setting of AF, women have a significantly higher risk of
stroke than men.2,8 The prevalence of stroke survivors
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is projected to increase along with the aging of the
population, especially among elderly women. Patients
older than 85 years of age make up 17% of all stroke
patients.2 Very elderly patients (age > 85 years) have
a higher risk-adjusted mortality and risk of disability,
have longer hospitalizations, receive less evidencedbased care and are less likely to be discharged to their
original place of residence.9
According to analyses from the U.S. Nationwide Inpatient
Sample, over the past decade, in-hospital mortality rates
after stroke have declined for every age except men older
than 84 years. Over the next 40 years (2010–2050), the
number of incident strokes is expected to more than
double, with the majority of the increase among patients
aged ≥ 75 years as well as in minority groups. Between
2012 and 2030, total direct medical stroke-related costs
are projected to triple, from $71.6 billion to $184.1
billion, with the majority of the projected increase in costs
arising from those 65–79 years of age.2 With a problem
of this magnitude, the health and economic implications
of thromboembolism associated with AF are farreaching.2,10 There is a growing need to better understand
the mechanisms that underlie aging-associated changes
in the cardiovascular system that predispose people to
AF and thromboembolism.6,11 Active research in these
areas has focused on identification of novel therapeutic
targets for prevention to reduce the incidence of AF and
its associated thromboembolic risk.12,13 This overview
highlights the pathogenesis and management of stroke
and thromboembolism associated with AF in elderly
patients.
Pathogenesis of Thromboembolism in Patients
With Atrial Fibrillation
Ischemic stroke in patients with AF usually is attributed
to embolism from thrombus in the left atrium or the
left atrial appendage (LAA), although as many as 25%
of strokes may be due to intrinsic cerebrovascular
disease.14 Hypercoagulability, left atrium or LAA stasis,
and endothelial injury reinforce the traditional Virchow
concept implicated in thrombogenesis.15 Therefore,
thrombogenic states, such as heart failure, diabetes,
aging or history of stroke, as well as conditions that can
lead to atrial stasis (poorly contracting dilated left atrium,
ventricle with spontaneous echocardiographic contrast,
LAA sludge, mitral stenosis) or endothelial dysfunction/
injury (hypertension, vascular disease) increase the risk
of stroke and thromboembolism in patients with AF.16-19
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Abnormalities in blood flow and vessels can be related
to the presence of structural heart disease or extrinsic
interventions such as cardioversion that can lead to atrial
stunning, promoting a prothrombotic state mostly within
the first 10 days after the cardioversion.17,18,20-24 Valvular
heart disease, especially mitral stenosis, increases the
risk of stroke in AF 17-fold.12
Episodes of AF themselves promote a procoagulant state
with an increase in markers of platelet activation (betathromboglobulin and platelet factor 4), thrombogenesis
(elevated fibrinogen, prothrombin fragment F1 + 2,
thrombin-antithrombin complexes, D-dimer levels)
and endothelial dysfunction or injury (elevated von
Willebrand factor, soluble E-selectin levels), independent
of the presence of structural heart disease, increasing the
likelihood of thromboembolism.6,11,16,22,23,25-30 Evidence
also points to endocardial or endothelial dysfunction
with decreased anticoagulant mechanisms –– such
as expression of nitric oxide synthase, tissue factor
pathway inhibitor and thrombomodulin –– and an
increase in procoagulant factors such as plasminogen
activator inhibitor-122,23,31 as a possible mechanism for
thromboembolism in the setting of AF. Inflammation
with elevated C-reactive protein and interleukin-6 is
associated with a prothrombotic state and an increase
in reactive oxygen species production that promotes
platelet hyperactivity and additional susceptibility to
thrombosis, contributing to an overall hypercoagulable
state in AF. This is particularly evident in the elderly
with aging-associated diseases, including diabetes,
heart failure and hypertension, which further increase
thrombogenicity.6,28,32-34 In addition, atrial stretch
associated with AF and myocardial dysfunction leads
to downregulation of thrombomodulin, which renders a
defective anticoagulant defense in AF patients and, thus,
predisposes these patients to stroke.35
Management of Thromboembolism in Elderly
Patients
The three main areas in the management of patients with
AF are maintenance of sinus rhythm, control of ventricular
rate response during AF, and prevention of complications
like stroke, peripheral thromboembolism, heart failure
and early mortality.1,36 Although rhythm control has
been thought to be better than rate control, the landmark
AFFIRM (Atrial Fibrillation Follow-up Investigation
of Rhythm Management) trial,37 the RACE (Rate
Control vs Electrical Cardioversion [for persistent atrial
Review

fibrillation]) trial,38 and the AF-CHF (Atrial Fibrillation
and Congestive Heart Failure)39 trial demonstrated that
AF patients who had a high risk of thromboembolism did
no better when treated with a strategy of pharmacologic
rhythm control than did AF patients treated with rate
control in regard to reducing overall or cardiovascular
mortality, hospitalization or risk of stroke.
Regardless of approach (rhythm vs rate control), these
findings indicate that maintenance of a therapeutic
level of anticoagulation is essential to reduce the risk of
thromboembolism in AF patients at high risk of stroke.40
In addition, the type of AF (paroxysmal, persistent or
permanent) or the absence of AF symptoms is not
predictive of thromboembolism.1 More than one-third
of patients with a history of AF treated with rhythm
control alone may have recurrent paroxysmal AF that

can be completely asymptomatic while still increasing
the risk of thromboembolism.41 Recent data in patients
with implantable loop recorder or cardiac devices
indicate that even AF episodes lasting for 6 minutes can
increase the risk of thromboembolism,42 and prolonged
monitoring of the rhythm in those with cryptogenic
stroke may reveal asymptomatic AF in up to 30% of the
patients.43 Therefore, prophylactic intervention to reduce
stroke risk should be considered in all AF patients at
high risk for stroke.
Risk Assessment for Stroke in AF Patients
The CHADS2, CHA2DS2-VASc and HAS-BLED
scoring systems (Table 1) are widely used to calculate
the risk of thromboembolism and bleeding, respectively,
in patients with nonvalvular AF.5,25,44 The CHADS2 risk
assessment system, developed after analysis of ischemic

Table 1. Comparison of CHADS2, CHA2DS2-VASc, and HAS-BLED Scores
CHADS2 scorea
Factor
CHF

HAS-BLED scoreb
Points
1

Factor
Hypertension

Hypertension

1

Age > 75 years

1

Diabetes
Previous stroke

Total score
0
1
2
3
4
5
6

CHA2DS2-VASc scorea

Points
1

Factor
Female

Age > 65 years

1

Age 65–74 years

1

Stroke

1

Age > 75 years

2

1

Bleeding history

1

CHF

1

2

Labile INRs

1

Hypertension

1

Drugs or alcohol abuse
Abnormal renal or liver
dysfunction

1 each

Diabetes mellitus

1

1 each

Vascular disease

1

History of stroke, TIA,
thromboembolism

2

Risk of stroke
(%/year)
1.9
2.8
4.0
5.9
8.5
12.5
18.2

Total score
0
1
2
3
4
5
6–9

Risk of
hemorrhage
(%/year)
1.13
1.02
1.88
3.74
8.70
12.50
>12.5

Total score
0
1
2
3
4
5
6
7
8
9

Points
1

Risk of
stroke
(%/year)
0.2
0.6
2.2
3.2
4.8
7.2
9.7
11.2
10.8
12.2

CHF, congestive heart failure; INR, international normalized ratio; TIA, transient ischemic attack.
Data in left and right columns extracted from January et al. 2014 AHA/ACC/HRS guideline for the management of patients
with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task
Force on Practice Guidelines and the Heart Rhythm Society. Circulation. 2014;130:2071-104.

a

Center column was adapted from Pisters et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major
bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093-100.

b
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stroke risk among patients with nonvalvular AF, assigns
a score of 1 for congestive heart failure, hypertension,
age ≥ 75 years and diabetes mellitus, respectively, and
a score of 2 for prior stroke/TIA or thromboembolism.45
There is an increase in stroke rate of approximately 2%
for each 1-point increase in CHADS2 score, ranging
from 1.9% with a score of 0 to 18.2% with a score of 6.1,45
The CHA2DS2-VASc score assigns 1 point each to
congestive heart failure, hypertension, age 65–74 years,
diabetes mellitus, female sex and vascular disease and 2
points each to prior stroke/TIA or thromboembolism and
age > 75 years. It is considered the preferred tool to assess
the embolic risk in patients with nonvalvular AF.25,46 A
CHA2DS2-VASc score of 2 or greater represents a high
risk for stroke that requires initiation of anticoagulation.
An important safety concern with use of antithrombotic
agents is the increased risk of major bleeding, requiring
hospitalization, transfusion or surgery, or intracranial
hemorrhage, which is associated with increased mortality
and disability. The risk of intracranial hemorrhage is
about 0.4% per year, which is lower than the risk of
ischemic stroke in the majority of AF patients with
CHA2DS2-VASc score ≥ 2, if not anticoagulated. To
quantify hemorrhage risk, several bleeding risk scores
have been published, including HAS-BLED, which is
based on the presence of hypertension, abnormal renal or
liver function, history of stroke, bleeding predisposition,
labile international normalized ratios (INRs), elderly
age (> 65 years), or use of excess alcohol or drugs that
promote bleeding.1,5,47-49 A score of 3 or higher indicates
a “high risk” for bleeding that may require closer
monitoring of anticoagulation and potential adverse
effects. Chronic kidney disease, although not included
in the CHA2DS2-VASc or CHADS2 risk prediction
models, is a strong predictor of stroke risk as well as
bleeding in patients with AF,18 therefore consideration for
anticoagulation requires careful risk/benefit assessment.
Pharmacological Strategies for Risk Reduction
of Stroke in AF
Anticoagulation with either warfarin (INR of 2.0 to 3.0)
or one of the novel oral anticoagulants (NOACs) such as
dabigatran, rivaroxaban, apixaban or edoxaban reduces
the risk of ischemic stroke or thromboembolism by almost
two-thirds in patients with nonvalvular AF and should be
considered in high-risk patients with a CHA2DS2-VASc
score of 2 or greater.1,25,27,33 Antiplatelet agents alone are
220 JPCRR • Volume 3, Issue 4 • Fall 2016

not very effective in reducing the risk of stroke (19%
reduction [95% confidence interval: 1%–35%]),1,20,26 and
most studies, with the exception of the Stroke Prevention
in Atrial Fibrillation-1 trial, revealed no significant
benefit in stroke reduction, especially in the older-elderly
(age > 75 years).1 Anticoagulants are associated with an
increased risk of bleeding; therefore, the risk-to-benefit
ratio needs to be carefully considered, especially in those
at relatively low risk for thromboembolism, such as those
with a CHA2DS2-VASc score less than 2. In patients
with a CHA2DS2-VASc score of 1 with a reported risk
of ischemic stroke varying from <1% to 2.7% per year,
no antithrombotic therapy or anticoagulation could be
recommended depending on the presence of risk factors,
with the highest risk in those 65–74 years old and with
diabetes.18,21 For very low-risk patients (CHA2DS2VASc score of 0), anticoagulant therapy usually is not
recommended and clinical judgment is required to make
an individualized decision.1
Despite the proven effectiveness of warfarin and
NOACs in the prevention of stroke in high-risk patients,
anticoagulants are underused for the prevention of stroke
in elderly patients with AF.30 In a recent study, common
contraindications to the use of anticoagulation in patients
≥ 75 years old were prior bleed (32%), patient refusal
(25%), frequent falls or frailty (25%), high bleeding risk
(20%), need for dual antiplatelet therapy (9%), unable
to adhere (5%), prior intracranial hemorrhage (5%),
comorbid illness (5%) and allergy (2%).50 In elderly
patients with multiple comorbidities and contraindications
for anticoagulation, despite a CHA2DS2-VASc score
necessitating anticoagulation (i.e. greater than 1), a
goals-of-care discussion may be warranted.
Role of Warfarin
Evidence for the efficacy of warfarin, a vitamin K
antagonist that affects clotting factors II, VII, IX and
X, in risk reduction for stroke in patients with AF at
moderate to high risk for thromboembolism comes from
randomized control trials conducted in the 1990s. These
trials demonstrated a significant two-thirds reduction in
the incidence of clinical stroke at an acceptable risk of
bleeding compared to placebo or the antiplatelet agent
aspirin.1,35 In addition, compared to no anticoagulant
therapy, the use of warfarin reduces the severity of
stroke and stroke mortality.19 The relative risk reduction
with warfarin in stroke patients was greater in patients
with a higher risk for stroke (rates of > 6% per year).
Review

In the general population, anticoagulation with warfarin
reduced the risk of stroke from >4.5% per year to
about 1.5% per year.1 The bleeding risk (1%–3% per
person-year) is higher during the initiation phase, with
concomitant illnesses affecting warfarin pharmacokinetics
or use of medicines or supplements that affect
hemostasis.35 The annual risk for intracranial hemorrhage
with warfarin in AF patients in recent studies is low
(0.2% to 0.4% per year) but is still up to two times higher
than the risk for nonanticoagulated patients (0.2%).17
Increasing age, prior stroke, hypertension and an
INR > 3 are the most important predictors of major
bleeding.10 For high-risk patients younger than 75
years old, a prothrombin time with an INR range
of 2 to 3 is safe and effective.29 For older patients
(> 75 years), a lower target INR level (2 to 2.5) could
be considered with close monitoring to reduce the
likelihood of bleeding. Maintaining the therapeutic
range of anticoagulation with warfarin is challenging
due to its narrow therapeutic index, which is affected
by various drug–drug and drug–food interactions as
well as chronic comorbidities or acute illnesses that can
reduce the time in the therapeutic range to 50%–65%.1,32
In addition, variability within the population in the
expression of genes involved in warfarin metabolism
(CYP2C9) and/or activation (VKORC) impacts
warfarin dosing, especially at initiation, leading to a
hypercoagulant state and risk for bleeding.51
The optimal approach to a patient with an elevated
INR and warfarin-associated coagulopathy depends
on the degree of INR elevation, ongoing bleeding
and its location (e.g. intracranial), and the underlying
thrombotic risk.52 In patients with serious or lifethreatening bleeding or those requiring an urgent surgery,
rapid and full reversal of warfarin’s effect is required
with intravenous vitamin K or 4-factor prothrombin
complex concentrate administration.48 Whereas, in
those with no or minor bleeding, warfarin can be held
without administration of a reversal agent, especially if
the underlying thrombotic risk is particularly high.
Novel Oral Anticoagulants: Alternatives to
Warfarin
To overcome some of the shortcomings of warfarin,
several newer oral anticoagulants have been developed
with a more predictable pharmacokinetic profile that
avoids the need for routine monitoring of anticoagulation
Review

and has fewer drug–food interactions; these are
expected to improve adherence to and persistence with
an anticoagulant regimen by the elderly.1,12 However,
renal function, bleeding and adherence still need to be
monitored in these patients. NOACs are divided into
those that directly inhibit thrombin or those with an
inhibitory effect on clotting factor Xa. The United States
has approved dabigatran (a direct thrombin inhibitor)
and rivaroxaban, apixaban and edoxaban (factor Xa
inhibitors) for risk reduction of stroke in patients with
nonvalvular AF. These NOACs have been compared
to warfarin in randomized controlled trials (Table 253-58)
and were found to be noninferior in risk reduction of
stroke, with a statistically significant reduced risk of
major, especially intracranial, bleeding in the elderly.
The risk of gastrointestinal bleeding was higher with
rivaroxaban than with warfarin.54 The initial evidence
of increased risk of myocardial infarction in patients on
rivaroxaban seen in the RE-LY trial was not confirmed
in subsequent analysis of large observational studies.59
Patients with prosthetic heart valves, rheumatic valve
disease, mitral stenosis or on protease inhibitors or other
drugs with a strong modulating effect on P-glycoprotein
or cytochrome 3A4 are not candidates for NOACs, and
warfarin remains the preferred anticoagulant.1,33
Predominant renal excretion remains a major limitation
for the use of NOACs in the elderly population. Drugs
like dabigatran and edoxaban cannot be used in patients
with advanced renal impairment (e.g. stage 4 or 5 chronic
kidney disease with creatinine clearance < 15 mL/min) and
require dosage adjustment for those with moderate renal
impairment (glomerular filtration rate < 60 mL/min/1.73
m2). Further research is needed to determine the utility and
safety of NOACs in elderly patients with chronic kidney
disease and end-stage renal disease. Limited information
is available about the efficacy and safety of these agents in
the older-elderly, but apixaban and edoxaban appear to
have a lower rate of bleeding compared to warfarin.33 No
head-to-head comparison between the new anticoagulants
in the elderly or those with moderate to severe renal
impairment has been performed. Further research in
defining the safety and efficacy of NOACs in patients
with renal impairment is needed.
Pooled results45 from the RE-LY (dabigatran),53
ARISTOTLE
(apixaban)55
and
ROCKET-AF
54
(rivaroxaban) trials indicate that, compared to warfarin,
NOACs in patients with nonvalvular AF are associated
www.aurora.org/jpcrr
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Table 2. Characteristics and Outcomes of Novel Anticoagulant Studies
Variable

RE-LY (2009)53

ROCKET-AF
(2011)54

ARISTOTLE
(2011)55

ENGAGE AF-TIMI 48
(2013)56

Design

Probe

Double-blind

Double-blind

Double-blind

Trial size

N=18,113

N=14,264

N=18,201

N=21,105

Median follow-up

2 years

1.9 years

1.8 years

2.8 years

Mean age

71.5 years

73 years

70 years

72 years

Male sex

63.5%

59.3%

64.5%

61.9%

Mean CHADS2

2.1

3.5

2.1

2.8

Mode of action

Oral direct thrombin
inhibitor
12–17 hours
Nonvalvular AF +
1 risk factor
Dabigatran 110 mg
b.i.d.
Dabigatran 150 mg
b.i.d.
Open-label warfarin
Stroke or systemic
embolism
Major bleeding

Oral direct factor Xa
inhibitor
5–13 hours
Nonvalvular AF +
2 risk factors
Rivaroxaban 20 mg
daily

Oral direct factor Xa
inhibitor
9–14 hours
Nonvalvular AF +
CHADS2 ≥ 1
Apixaban 5 mg b.i.d.

Oral direct factor Xa
inhibitor
10–14 hours
Nonvalvular AF +
CHADS2 ≥ 2
Edoxaban 30 mg daily
Edoxaban 60 mg daily

Blinded warfarin
Stroke or systemic
embolism
Major bleeding +
clinically relevant
nonmajor bleeding
2.4% warfarin
2.1% rivaroxaban

Blinded warfarin
Stroke or systemic
embolism
Major bleeding

Blinded warfarin
Stroke or systemic
embolism
Major bleeding

1.6% warfarin
1.27% apixaban*

1.5% warfarin
1.61% edoxaban 30 mg*
1.18% edoxaban 60 mg*

3.4% warfarin
3.6% rivaroxaban

3.09% warfarin
2.13% apixaban*

3.43% warfarin
1.61% edoxaban 30 mg*
2.75% edoxaban 60 mg*

0.7% warfarin
0.5% rivaroxaban*

0.8% warfarin
0.33% apixaban

0.85% warfarin
0.26% edoxaban 30 mg*
0.39% edoxaban 60 mg*

1.1% warfarin
0.9% rivaroxaban

0.61% warfarin
0.53% apixaban

0.75% warfarin
0.70% edoxaban 30 mg
0.89% edoxaban 60 mg

$55,757

$24,312

$67,320 – edoxaban
30 mg
$46,393 – edoxaban
60 mg

Half-life
Inclusion criteria
Intervention

Comparator
Primary efficacy
Primary safety
Stroke/systemic
embolism

1.71% warfarin
1.54% dabigatran
110 mg
1.11% dabigatran
150 mg*
Major bleeding
3.57% warfarin
2.87% dabigatran
110 mg*
3.32% dabigatran
150 mg
Intracranial hemorrhage 0.74% warfarin
0.23% dabigatran
110 mg*
0.3% dabigatran
150 mg*
Myocardial infarction
0.64% warfarin
0.82% dabigatran
110 mg
0.81% dabigatran
150 mg
Incremental cost
$66,354 – dabigatran
per QALY gained
110 mg
(vs warfarin)57,58
$20,797 – dabigatran
150 mg
*P<0.05.
QALY, quality-adjusted life-year.

with a significant reduction of stroke and major bleeding,
including hemorrhagic stroke and overall mortality. The
meta-analysis also indicated a trend toward reduced
major bleeding.60
222 JPCRR • Volume 3, Issue 4 • Fall 2016

The anticoagulant effect of the approved NOACs occurs
and declines rapidly; therefore, the recommended
dosage regimen needs to be closely followed to avoid
any thromboembolic complications resulting from
Review

inadequate anticoagulation.1,12 If a dose of dabigatran
or apixaban with a twice-daily regimen is missed, the
forgotten dose can be taken up to 6 hours after the
scheduled ingestion;12 if missed for longer than 6 hours,
the missed dose should be skipped and the regularly
scheduled dose taken on time. If more than one dose
was taken within the period of 6 hours, the planned
dose at 12 hours should be skipped with resumption
of the regular dose at the next scheduled time. For
rivaroxaban with once-daily administration, the missed
dose can be taken up to 12 hours later, or skipped after
12 hours, with resumption of the next scheduled dose.
For double dosing, rivaroxaban can be continued at the
regular interval without skipping the next dosage.54 If
a dose of edoxaban is missed, the dose should be taken
as soon as possible on the same day. Dosing should
resume the next day according to the normal dosing
schedule. The dose should not be doubled to make up for
a missed dose. Patient education about nonadherence,
risk of stroke or overdose, risk of bleeding, potential
side effects and drug–food interactions is especially
important in the elderly.61
Reversal Agents for NOACs
Lack of readily available reversal agents for the
anticoagulant effect of NOACs was one of the
serious concerns that recently has been addressed.62
Idarucizumab (Praxbind), a specific antibody against
dabigatran, completely reverses the anticoagulant effect
of dabigatran within minutes and has been approved by
the U.S. Food and Drug Administration (FDA) for this
purpose.63 Andexanet, a recombinant modified human
factor Xa decoy protein, reverses the anticoagulant
activity of apixaban and rivaroxaban within minutes
after administration and for the duration of infusion,
without evidence of clinical toxic effects.64 This drug
is currently under investigation and is not yet FDAapproved for use as a reversal agent.
Drug–Drug Interactions With NOACs
All NOACs are substrates of the P-glycoprotein
transport system and are thus susceptible to drug
interactions with both inhibitors and inducers of
this system (Table 3).65-69 In addition, rivaroxaban
undergoes hepatic transformation primarily via the
cytochrome P-450 system (CYP), which includes
both the 3A4 and 2J2 families of enzymes. Due to
the involvement of CYP3A4, plasma concentrations
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of rivaroxaban can become elevated or reduced in the
presence of strong inhibitors or inducers.66,67 Changes
in plasma concentrations are most pronounced when
rivaroxaban is administered with medications that affect
both CYP3A4 and P-glycoprotein, which can result in
increased or decreased anticoagulation depending on the
interacting agent.65 Similar to rivaroxaban, apixaban is a
substrate for both CYP3A4 and P-glycoprotein, making
it susceptible to numerous drug–drug interactions,
particularly with agents that affect both pathways.67,70
Edoxaban is also a substrate of cytochrome P-450 3A4
(CYP3A4).71 There is an increased risk of bleeding
associated with concurrent use of NOACs with other
anticoagulants, antiplatelet agents and nonsteroidal antiinflammatory drugs.
Novel Nonpharmacological Strategies to
Reduce Thromboembolism
Most patients with AF at high risk of stroke based on
the CHA2DS2-VASc score should be therapeutically
anticoagulated to reduce said risk. However, the risk
of bleeding with anticoagulants remains high in the
elderly and other patients with unstable gait, a history
of intracranial or severe recurrent gastrointestinal bleed,
or thrombocytopenia or coagulation defects. This risk
could be unacceptably high, highlighting the need for
approaches to reduce the risk of stroke without increasing
the risk of bleeding. Based on observations that left atrial
clots are localized to the LAA more than 90% of the time,9
surgical excision of the LAA or mechanical devices that
occlude or exclude the LAA from circulation by ligating
its opening into the left atrium have been developed for
reduction in thromboembolic risk.
Surgical Excision or Transcutaneous Occlusion/
Isolation of Left Atrial Appendage: In AF patients
undergoing open heart surgery for mitral valve or the
Maze procedure for AF, surgical ligation, occlusion or
amputation of the LAA has been performed without
any added morbidity and with reduction in the risk of
thromboembolism as compared to those without this
procedure.9 However, incomplete closure of the LAA
has been documented in a large number of patients
who continue to be at risk for thromboembolic events.72
Stand-alone thoracoscopic left atrial appendectomy in
patients with AF and prior thromboembolism who had
contraindications to oral anticoagulation demonstrated
the feasibility of this approach along with reduction in
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Table 3. Characteristics and Outcomes of Novel Anticoagulant Studies
CYP3A4
inhibition

CYP3A4
induction

–

–

Increased
concentrations
Increased
concentrations

Decreased
concentrations
Decreased
concentrations

Edoxaban

–

–

Examples

Strong
Azole antifungals
Clarithromycin
Conivaptan
Grapefruit
HIV protease
inhibitors
Holkira pak
Idelalisib
Nefazodone
Posaconazole
Technivie
Telithromycin
Viekira Pak
Voriconazole

Carbamazepine
Dexamethasone
Fosamprenavir
Lumacaftor
Nevirapine
Phenobarbital
Phenytoin
Rifabutin
Rifapentine
Rifampin
St. John's wort

NOAC
Dabigatran
Rivaroxaban
Apixaban

RP-glycoprotein
inhibition

P-glycoprotein
induction

Increased
concentrations
Increased
concentrations
Increased
concentrations
Increased
concentrations

Decreased
concentrations
Decreased
concentrations
Decreased
concentrations
Decreased
concentrations

Strong
Amiodarone
Azole antifungals
Clarithromycin
Cyclosporine
Dronaderone
Flibanserin
Lapatinib
Nicardipine
Quinidine
Ritonavir
Verapamil

Strong
Carbamazepine
Phenobarbital
Phenytoin
Rifampin
St. John's wort

Other notables
(also at least
moderately inhibit
CYP3A4)
Conivaptan
Crizotinib
Diltiazem
Erythromycin
Grapefruit
HIV protease inhibitors
Idelalisib
Imatinib
Nefazodone
Netupitant
Posaconazole
Telithromycin

Moderate
Aprepitant
Ciprofloxacin
Crizotinib
Diltiazem
Dronedarone
Erythromycin
Fluconazole
Imatinib
Netupitant
Verapamil

Other notables
(also induce
CYP3A4)
Dexamethasone
Fosamprenavir
Lumacaftor
Nevirapine
Rifabutin
Rifapentine

HIV, human immunodeficiency virus; NOAC, novel oral anticoagulant.

thromboembolism.73 Surgical exclusion of LAA using
the AtriClip device (AtriCure Inc., Mason, OH) also
can be performed successfully in patients undergoing
open chest surgery or using a right mini-thoracotomy
incision.74 Findings from the LAAOS (Left Atrial
Appendage Occlusion Study) pilot study demonstrated
the safety and feasibility of LAA occlusion during cardiac
surgery; and the efficacy of this approach is being tested
in a large randomized trial (LAAOS III) in patients
undergoing cardiac surgery.75,76 A 59% risk reduction
of stroke compared with the expected rate based on
CHAD2DS2-VASc score and a 61% risk reduction of
bleeding compared with the expected rate based on
HAS-BLED score was demonstrated in observational
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studies of the Amplatzer™ Cardiac Plug and secondgeneration Amplatzer Amulet™ endovascular LAA
occluder devices (St. Jude Medical Inc., St. Paul, MN),
not yet approved by the FDA.77,78 The Amplatzer cardiac
plug has received European regulatory approval and is
available for clinical use in Europe.
Various percutaneous approaches for LAA occlusion
have been developed utilizing a transfemoral transseptal
puncture to enable device implant into the LAA
or a hybrid transseptal and epicardial approach for
LAA closure.9 Among these, the Watchman™ device
(Boston Scientific Corp., Marlborough, MA), a selfexpandable nitinol cage deployed in the LAA using a
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transseptal approach, was assessed in two randomized
trials (PROTECT AF and PREVAIL) in patients
with nonvalvular AF eligible for oral anticoagulation
(CHADS2 score > 1).79,80 A comparable efficacy and safety
of the Watchman device to warfarin for the prevention
of stroke and systemic embolization was demonstrated
in PROTECT AF.79 In the follow-up PREVAIL trial, in
high-risk patients with nonvalvular AF, noninferiority
of LAA occlusion to warfarin anticoagulation was not
achieved for the overall efficacy (composite of stroke,
systemic embolism and cardiovascular/unexplained
death); however, noninferiority was demonstrated
for ischemic stroke prevention or systemic embolism
> 7 days postprocedure.80 Based on these results,
the Watchman device was approved by the FDA for
patients with nonvalvular AF for whom long-term
anticoagulation is indicated and who are able to tolerate
warfarin for at least 6 weeks after device implantation.
The use of Watchman in high-risk AF patients ineligible
for oral anticoagulation was tested in ASAP (Aspirin
Plavix Feasibility Study With Watchman Left Atrial
Appendage Closure Technology), a prospective,
multicenter, nonrandomized study that demonstrated
a lower incidence of stroke or systemic embolism
compared to those taking aspirin or clopidogrel.81
The Lariat® (SentreHEART Inc., Redwood City, CA),
an LAA exclusion device currently being used “offlabel” in the United States for AF patients, consists
of a pre-tied suture enclosed in a closed snare that is
deployed transcutaneously using a hybrid transfemoral
catheter-based endocardial and epicardial approach.82
In the U.S. Transcatheter LAA Ligation Consortium’s
retrospective assessment of 154 patients, the procedural
success rate was 86% with major complication rate of
9.7%, including major bleeds and serious pericardial
effusions.83 Cases of death; cardiac laceration,
perforation or LAA detachment from the heart;
bleeding; or cardiac tamponade have been reported in
a safety communication by the FDA.84 The long-term
effectiveness of the Lariat with respect to reducing
stroke or its safety relative to other approaches needs to
be defined in randomized controlled trials.82
In patients with AF who have a high risk of stroke
and contraindication to long-term anticoagulation,
percutaneous LAA closure by the Watchman device9
or surgical excision at the time of cardiac surgery1 are
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reasonable options to reduce the risk of stroke in lieu
of taking long-term anticoagulation. Since a significant
proportion of strokes in AF patients may originate from
aortic arch plaques, the risk of stroke with LAA occlusion
may persist; in select patients, carotid diverters aimed at
diverting emboli from intracranial circulation may be
helpful but require further investigation.82
Atrial Ablation of AF Substrate: Per the current
guidelines, AF catheter ablation is useful for
symptomatic paroxysmal AF refractory or intolerant
to at least one class I or III antiarrhythmic medication
when a rhythm-control strategy is desired.1,85 AF
catheter ablation to restore sinus rhythm should not be
performed with the sole intent of obviating the need for
anticoagulation,1 especially since the long-term efficacy
of radiofrequency catheter ablation in reducing the risk
of stroke, particularly in elderly patients with multiple
risk factors, is not known.
Radiofrequency catheter ablation of the left atrium has
been shown to effectively maintain a majority of patients
in sinus rhythm and promote atrial reverse remodeling
with a decrease in left atrial volumes and dimensions
as well as an improvement in contractility.86,87 In a
study of AF patients mostly younger than 65 years old,
of whom 56% had one or more risk factor for stroke,
successful ablation of the left atrium was associated
with discontinuation of anticoagulation in patients
with or without risk factors for stroke (except for those
older than 65 years old or with a history of stroke).88 A
thromboembolic event rate of 1.1% within 2 weeks of
ablation emphasized the need for anticoagulation for at
least 3 months after a procedure, which would facilitate
atrial remodeling with a return to sinus rhythm, thereby
potentially reducing the risk of thromboembolism. A
meta-analysis of eight randomized controlled trials
comprising 844 patients showed that radiofrequency
catheter ablation decreased atrial tachyarrhythmia
recurrence by 71% (P<0.00001). Fewer complications
and adverse events were reported in the ablation
group compared to the control group.89 Despite these
preliminary results, anticoagulation with warfarin or
NOACs should be continued in patients at high risk for
thromboembolism (i.e. CHA2DS2-VASc score ≥ 2).
Surgical ablation also aims to eliminate AF by the use of
atrial incisions that prevent propagation of arrhythmia
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while preserving the sinus node and atrial contractility.
The Cox Maze procedure ablates the atrial substrate for
AF and removes the LAA to reduce risk of stroke by
maintaining sinus rhythm and removing the major site
for thrombus formation within the heart.90,91 Despite
promising findings of surgical follow-up studies,
prospective, randomized, multicenter trials are needed
to obtain definitive evidence for the most effective
treatment approach, energy source for ablation, specific
areas of ablation and the true success rate in reducing
risk of stroke and AF recurrence.1
Summary
With the aging of the U.S. population and a projected
increase in the prevalence of atrial fibrillation in
Americans from about 2.3 million in 2006 to more than
15 million by the year 2050, AF is a major public health
problem.92-94 Advances in our understanding of the
aging-associated changes that form the substrate of AF
and thromboembolism in the elderly remain inadequate
to fully promote the design of safe and effective
strategies to prevent AF and reduce the associated
risk of stroke. Many recognized markers imply a risk
of thromboembolism in AF patients, yet the specific
mechanisms that initiate and maintain a thrombotic state
with AF remains to be fully understood. Regardless of
treatment approach (either rate or rhythm control),
anticoagulation is of paramount importance in decreasing
the risk of thromboembolism in high-risk patients. Both
warfarin and newer oral anticoagulants are effective in
reducing the risk of thromboembolism in patients with
nonvalvular AF but continue to carry risks of bleeding
that limit their use in select elderly patients, particularly
those with renal impairment. Further studies comparing
newer anticoagulation in select patient populations are
needed to define specific clinical situations in which one
anticoagulant offers a superior benefit-to-risk profile
relative to other available treatments.
The management of elderly patients predisposed to
thromboembolism mandates addressing the difficult
problem of balancing the risk of bleeding with longterm anticoagulation against its proven benefit in
reducing stroke risk. Nonpharmacological strategies
are limited, not applicable to all patients and require
further investigation to prove their equivalence or
superiority to anticoagulants in reducing the risk
of thromboembolism or other complications in the
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elderly. Age alone should not be the limiting factor
for anticoagulation, which should be considered in
all patients unless clearly contraindicated.12 Further
research is needed to identify initiating factors and
critical mediators of thromboembolism and to delineate
pathways altered by aging that potentiate the risk for
AF and thromboembolism.11,95 With better patient
risk-stratification and the design of more appropriate
therapeutic strategies, AF-associated thromboembolic
risk could be further reduced in elderly patients.
Patient-Friendly Recap
• Atrial fibrillation (AF) is an abnormal heart
rhythm that greatly increases an individual’s risk
for suffering a stroke.
• To prevent this, many patients with AF take
anticoagulant medication such as warfarin.
• The authors report the current state of evidence
regarding ways to prevent stroke in elderly
patients with AF, who often have complex
conditions for which use of anticoagulants may
raise the risk of bleeding.
• They concluded anticoagulation is still the most
proven treatment for AF in patients at high risk
of stroke, but elderly patients should be more
closely monitored to avoid potentially dangerous
bleeding incidents.
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